CAR-T Archives

News and Trends 31 Oct 2015

What Happened this Week? An Incredible Woman, CRISPR deal, CAR-T milestone

Monday: Wow, Europe’s leading CRISPR Biotech signs monster €2.29 Billion Deal Tuesday: Meet the French Woman who started a Biotech to Save her Daughter from a Rare Disease Wednesday: Dragen Bio-Processor: UK Partnership to Finally Sequence Domestic Wheat Genome Thursday: Cellectis UCART Milestone: One step closer to a Universal CAR-T Therapy for Blood Cancer Friday: Purple GMO Tomatoes […]

October 31, 2015 - 1 minutemin - By Philip Hemme

News and Trends 29 Oct 2015

Cellectis UCART Milestone: One step closer to a Universal CAR-T Therapy for Blood Cancer

Cellectis is a leader in immuno-oncology CAR-T therapies from France, which might revolutionise cancer treatments. Now, the next step in the CAR-T campaign is to step away from personalised (autologous) therapies, which are time-consuming and expensive, to instead produce an allogenic version available to all. So, what is CAR-T? You can read a more in-depth […]

October 29, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 29 Oct 2015

ERRATUM: Celyad’s US patent on TCR-deficient allogeneic CAR-T cells

ERRATUM: I published a first article on Celyad’s new patent on last Tuesday where I made an error of judgement. Celyad’s US patent covers allogeneic CAR-T modified to reduce immunogenicity. In my previous article, I wrote that Celyad stated having obtained the first US patent on CAR-T, which is wrong. Last Tuesday, Celyad announced having […]

October 29, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 21 Oct 2015

CAR-T Wannabe? Immuno-oncology Start-up snowballs $102M for Series A Fund

Gritstone Pharmaceuticals is a US start-up which will focus on R&D of its new CAR-T cancer therapy technique: tumor-specific neo-antigen (TSNA). An impressive financial syndicate is backing its launch this month, having achieved a £102M series A pot for their lung cancer research. This cash is a clear indication that this start-up has the 3 […]

October 21, 2015 - 3 minutesmins - By Dani Bancroft

In Depth 20 Oct 2015

The Ultimate Review on how Biotech Changed Cancer Treatment

You have roughly 50% chance of developing a cancer in your life and 25% of dying from it. How to cure it? Biotech played and will continue to play an essential role in Cancer, ranging from monoclonal antibodies, immuno-oncology, CAR-T and everything in between. Cancer is the degeneration of one type of cell within an […]

October 20, 2015 - 10 minutesmins - By Jerome Topsent

News and Trends 14 Sep 2015

Leading Cause of blindness has new US & EU Orphan Drug Designation Immunotherapy

TxCell, from Nice (Fr), has been granted EU and US Orphan Drug Designation for its T-cell based therapy for autoimmune uveitis – an eye inflammatory disease responsible of 10-15% legal blindness in developed countries. TxCell is a spin-off from France’s National Institute for Health and Medical Research (Inserm), with a pipeline including a phase II […]

September 14, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 4 Sep 2015

CAR-T therapy first clinical proof: Patient lives cancer-free 5 years on

A pioneering CAR-T cell therapy study from Novartis and the University of Pennsylvania demonstrates the impressive potential of the next-generation therapy. Five years after the start of the study, three patients have achieved complete remission and remain cancer-free. Here it is, the proof that the hype about CAR-T cell therapy was no hollow promise. Penn’s […]

September 4, 2015 - 4 minutesmins - By Philip Hemme

News and Trends 22 Jul 2015

Adaptimmune’s TCR Therapy Proves its Superiority over its Immuno-oncology Competitors

Adaptimmune Therapeutics, an oxford-based company focusing on the use of T-cell therapies to treat cancer, announced today that data from its Phase I/II study in patients with multiple myeloma has been published in Nature Medicine. This is the first report on TCR engineered T-cell therapy that shows durable persistence in patients! After its successful intoduction on […]

July 22, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 20 Jul 2015

Theravectys’ HIV Cure on the Road to Success

Theravectys just announced positive results of its HIV drug candidate in a phase I/II study. The therapeutic vaccine using lentivirus could be the first cure available for the 35 million people currently suffering from this worldwide epidemic. Paris-based Theravectys presented detailed results from its phase I/II study at the 2015 Towards an HIV Cure Symposium in Vancouver, Canada. The trial currently enrolled 38 HIV-positive patients […]

July 20, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 15 Jul 2015

How Servier saved Cellectis, the French CAR-T Miracle

Cellectis, the €1bn CAR-T company, just announced it reached a significant milestone in its collaboration with Servier. Surprisingly, early 2014, Cellectis and its 300 employees were only three months away from bankruptcy, mainly because of the competing gene-editing technology CRISPR. How and why did Servier save them? Let’s find out. Cellectis was founded in 1999 in Paris and […]

July 15, 2015 - 5 minutesmins - By Philip Hemme

News and Trends 25 Jun 2015

Video: Discover How CAR-T Therapies are Working

It’s becoming a habit for us to talk about CAR-T therapies. It’s basically the next wave of treatments against cancer and already promises to be the future blockbusters and growth drivers of the whole Biotech industry. Cellectis, a leading company in this field, just published a cool video about CAR-Ts. Of course, they’re describing more specifically their own therapy, […]

June 25, 2015 - 1 minutemin - By Joachim Eeckhout

News and Trends 19 Jun 2015

Celyad, the new face of Cardio3, is launching an IPO on NASDAQ

[UPDATE 19/06/2015]: Yesterday, Celyad launched its IPO on NASDAQ and the closing is expected to occur on 24 June 2015. Celyad, formely known as Cardio3, is preparing to cross the Atlantic to launch an IPO on NASDAQ. The company, which is already listed on Euronext Paris and Euronext Brussels, aims to raise €103.2M ($115 million) on […]

June 19, 2015 - 2 minutesmins - By Lourdes Riquelme

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

CAR-T

What Happened this Week? An Incredible Woman, CRISPR deal, CAR-T milestone

Cellectis UCART Milestone: One step closer to a Universal CAR-T Therapy for Blood Cancer

ERRATUM: Celyad’s US patent on TCR-deficient allogeneic CAR-T cells

CAR-T Wannabe? Immuno-oncology Start-up snowballs $102M for Series A Fund

The Ultimate Review on how Biotech Changed Cancer Treatment

Leading Cause of blindness has new US & EU Orphan Drug Designation Immunotherapy

CAR-T therapy first clinical proof: Patient lives cancer-free 5 years on

Adaptimmune’s TCR Therapy Proves its Superiority over its Immuno-oncology Competitors

Theravectys’ HIV Cure on the Road to Success

How Servier saved Cellectis, the French CAR-T Miracle

Video: Discover How CAR-T Therapies are Working

Celyad, the new face of Cardio3, is launching an IPO on NASDAQ

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!